DOI:

TAVI for patients with severe bicuspid aortic valve stenosis

Hayashida K., Bouvier E., Lefèvre T., Chevalier B., Hovasse T., Romano M., Garot P., Watanabe Y., Farge A., Donzeau-Gouge P., Cormier B., Morice M.C.

Single and multicentre TAVI registries

TAVI for patients with severe bicuspid aortic valve stenosis

Aims: A bicuspid aortic valve (BAV) is regarded as a relative contraindication to transcatheter aortic valve implantation (TAVI) due to the risk of uneven expansion of the bioprosthesis. The purpose of this study was to evaluate the efficacy and safety of TAVI in patients with BAV.

Methods and results: Of 470 patients included in our prospective TAVI database (October 2006 to January 2012), 229 consecutive patients undergoing both echocardiography and multidetector computed tomography (MDCT) were analysed. We compared clinical outcomes in patients with vs. without BAV. In this series of 229 patients, BAV was detected by MDCT in 21 patients (9.2%). BAV was identified by transthoracic and/or transoesophageal echocardiography in 9/21 patients only. The BAV group consisted of type 1 L-R (16 cases), type 1 R-N (1), type 1 L-N (1) and type 2 L-R and L-N (3). The mean length of raphe measured by CT was 12.7±2.7 mm (range: 7-16 mm). Patients were 83.1±6.6 years old and EuroSCORE 20.0±11.4%. The BAV group was similar to the non-BAV group except for diabetes (4.8 vs. 24.0%, p=0.04). The aortic annulus diameter was not significantly larger by MDCT (24.7±3.0 vs. 23.7±1.9 mm, p=0.14) in BAV patients. CoreValve was used more frequently in the BAV group (47.6 vs. 16.3%, p<0.01). There was no significant difference in device success (100 vs. 92.8%, p=0.23), risk of annulus rupture (0 vs. 1.4%, p=0.75) or valve migration (0 vs. 1.4%, p=0.75) in BAV vs. non-BAV patients. Post-procedural mean gradient (10.0±3.4 vs. 9.7±4.1 mmHg, p=0.78), aortic regurgitation ≥2/4 (19.0 vs. 14.9%, p=0.54), 30-day mortality (4.8 vs. 8.2%, p=0.49) and 30-day combined safety point (14.3 vs. 13.5%, p=0.56) were also similar in both groups. In the BAV group there were no significant differences in post-procedural mean pressure gradient (9.3±3.2 vs. 10.8±3.6 mmHg, p=0.36) and post-procedural AR grade ≥2 (9.1 vs. 30.0%, p=0.31) between Edwards valve and CoreValve.

Conclusions: In patients with BAV, TAVI is associated with high rates of success, low complication rates, similar efficacy and acceptable outcomes as in non-BAV patients.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA10 Sep 18, 2016
Transcatheter aortic valve implantation in bicuspid aortic valve stenosis
Perlman G et al
free

Editorial

10.4244/EIJ-E-23-00037 Aug 21, 2023
Bicuspid is different
Bleiziffer S
free

Editorial

10.4244/EIJ-E-22-00015 Jun 24, 2022
Durability of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: the last missing piece?
Van Belle E and Vincent F
free

Clinical Research

10.4244/EIJ-D-21-00734 Jun 24, 2022
Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis
Zhou D et al
free

Original Research

10.4244/EIJ-D-24-00869 Jan 20, 2025
TAVI with the ACURATE neo2 in severe bicuspid aortic valve stenosis: the Neo2 BAV Registry
Rück A et al

Debate

10.4244/EIJ-E-22-00042 Nov 18, 2022
TAVI in younger patients with bicuspid aortic stenosis: pros and cons
Blackman D et al
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved